BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 15608077)

  • 1. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist.
    Fox GB; Esbenshade TA; Pan JB; Radek RJ; Krueger KM; Yao BB; Browman KE; Buckley MJ; Ballard ME; Komater VA; Miner H; Zhang M; Faghih R; Rueter LE; Bitner RS; Drescher KU; Wetter J; Marsh K; Lemaire M; Porsolt RD; Bennani YL; Sullivan JP; Cowart MD; Decker MW; Hancock AA
    J Pharmacol Exp Ther; 2005 Apr; 313(1):176-90. PubMed ID: 15608077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two novel and selective nonimidazole H3 receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization.
    Fox GB; Pan JB; Radek RJ; Lewis AM; Bitner RS; Esbenshade TA; Faghih R; Bennani YL; Williams M; Yao BB; Decker MW; Hancock AA
    J Pharmacol Exp Ther; 2003 Jun; 305(3):897-908. PubMed ID: 12606600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties.
    Esbenshade TA; Fox GB; Krueger KM; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan L; Wetter J; Marsh K; Bennani YL; Cowart MD; Sullivan JP; Hancock AA
    J Pharmacol Exp Ther; 2005 Apr; 313(1):165-75. PubMed ID: 15608078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
    Cowart M; Faghih R; Curtis MP; Gfesser GA; Bennani YL; Black LA; Pan L; Marsh KC; Sullivan JP; Esbenshade TA; Fox GB; Hancock AA
    J Med Chem; 2005 Jan; 48(1):38-55. PubMed ID: 15634000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects.
    Esbenshade TA; Krueger KM; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Fox GB; Faghih R; Bennani YL; Williams M; Hancock AA
    J Pharmacol Exp Ther; 2003 Jun; 305(3):887-96. PubMed ID: 12606603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.
    Esbenshade TA; Fox GB; Krueger KM; Baranowski JL; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan JB; Faghih R; Bennani YL; Williams M; Hancock AA
    Biochem Pharmacol; 2004 Sep; 68(5):933-45. PubMed ID: 15294456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist.
    Esbenshade TA; Browman KE; Miller TR; Krueger KM; Komater-Roderwald V; Zhang M; Fox GB; Rueter L; Robb HM; Radek RJ; Drescher KU; Fey TA; Bitner RS; Marsh K; Polakowski JS; Zhao C; Cowart MD; Hancock AA; Sullivan JP; Brioni JD
    J Pharmacol Exp Ther; 2012 Oct; 343(1):233-45. PubMed ID: 22815533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective H3 receptor (H3R) blockade: broad efficacy in cognition and schizophrenia.
    Fox GB; Esbenshade TA; Pan JB; Browman KE; Zhang M; Ballard ME; Radek RJ; Miner H; Bitner RS; Krueger KM; Yao BB; Faghih R; Rueter LE; Komater VA; Drescher KU; Buckley MJ; Sullivan JP; Cowart MD; Decker MW; Hancock AA
    Inflamm Res; 2005 Apr; 54 Suppl 1():S23-4. PubMed ID: 15928819
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of histamine H(3) receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup.
    Fox GB; Pan JB; Esbenshade TA; Bennani YL; Black LA; Faghih R; Hancock AA; Decker MW
    Behav Brain Res; 2002 Apr; 131(1-2):151-61. PubMed ID: 11844582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective brain region activation by histamine H₃ receptor antagonist/inverse agonist ABT-239 enhances acetylcholine and histamine release and increases c-Fos expression.
    Munari L; Provensi G; Passani MB; Blandina P
    Neuropharmacology; 2013 Jul; 70():131-40. PubMed ID: 23380305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the histamine H₃ receptor antagonist ABT-239 on cognition and nicotine-induced memory enhancement in mice.
    Kruk M; Miszkiel J; McCreary AC; Przegaliński E; Filip M; Biała G
    Pharmacol Rep; 2012; 64(6):1316-25. PubMed ID: 23406742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models.
    Medhurst AD; Atkins AR; Beresford IJ; Brackenborough K; Briggs MA; Calver AR; Cilia J; Cluderay JE; Crook B; Davis JB; Davis RK; Davis RP; Dawson LA; Foley AG; Gartlon J; Gonzalez MI; Heslop T; Hirst WD; Jennings C; Jones DN; Lacroix LP; Martyn A; Ociepka S; Ray A; Regan CM; Roberts JC; Schogger J; Southam E; Stean TO; Trail BK; Upton N; Wadsworth G; Wald JA; White T; Witherington J; Woolley ML; Worby A; Wilson DM
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1032-45. PubMed ID: 17327487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Potent and Selective Histamine H
    Hino N; Marumo T; Kotani M; Shimazaki T; Kaku-Fukumoto A; Hikichi H; Karasawa JI; Tomishima Y; Komiyama H; Tatsuda E; Nozawa D; Nakamura T; Chaki S
    J Pharmacol Exp Ther; 2020 Nov; 375(2):276-285. PubMed ID: 32862143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histamine H3 receptor antagonism by ABT-239 attenuates kainic acid induced excitotoxicity in mice.
    Bhowmik M; Saini N; Vohora D
    Brain Res; 2014 Sep; 1581():129-40. PubMed ID: 24952295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and SAR of 5-amino- and 5-(aminomethyl)benzofuran histamine H3 receptor antagonists with improved potency.
    Sun M; Zhao C; Gfesser GA; Thiffault C; Miller TR; Marsh K; Wetter J; Curtis M; Faghih R; Esbenshade TA; Hancock AA; Cowart M
    J Med Chem; 2005 Oct; 48(20):6482-90. PubMed ID: 16190774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between ex vivo receptor occupancy and wake-promoting activity of selective H3 receptor antagonists.
    Le S; Gruner JA; Mathiasen JR; Marino MJ; Schaffhauser H
    J Pharmacol Exp Ther; 2008 Jun; 325(3):902-9. PubMed ID: 18305012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structurally novel histamine H3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats.
    Medhurst AD; Briggs MA; Bruton G; Calver AR; Chessell I; Crook B; Davis JB; Davis RP; Foley AG; Heslop T; Hirst WD; Medhurst SJ; Ociepka S; Ray A; Regan CM; Sargent B; Schogger J; Stean TO; Trail BK; Upton N; White T; Orlek B; Wilson DM
    Biochem Pharmacol; 2007 Apr; 73(8):1182-94. PubMed ID: 17276409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease.
    Bitner RS; Bunnelle WH; Decker MW; Drescher KU; Kohlhaas KL; Markosyan S; Marsh KC; Nikkel AL; Browman K; Radek R; Anderson DJ; Buccafusco J; Gopalakrishnan M
    J Pharmacol Exp Ther; 2010 Sep; 334(3):875-86. PubMed ID: 20504913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist.
    Ligneau X; Lin J; Vanni-Mercier G; Jouvet M; Muir JL; Ganellin CR; Stark H; Elz S; Schunack W; Schwartz J
    J Pharmacol Exp Ther; 1998 Nov; 287(2):658-66. PubMed ID: 9808693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization.
    Decker MW; Brioni JD; Sullivan JP; Buckley MJ; Radek RJ; Raszkiewicz JL; Kang CH; Kim DJ; Giardina WJ; Wasicak JT
    J Pharmacol Exp Ther; 1994 Jul; 270(1):319-28. PubMed ID: 7913497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.